Pharmacogenetics of antidepressants

Crisafulli, Concetta; Fabbri, Chiara; Porcelli, Stefano; Drago, Antonio; Spina, Edoardo; De Ronchi, Diana; Serretti, Alessandro

doi:10.3389/fphar.2011.00006

Cited by 113Neurotransmitter Receptor Influence on BehaviorTreatment of Major DepressionPharmacogenetics and Drug Metabolism

Pharmacogenetics of antidepressants

Open access

Crisafulli, Concetta, Fabbri, Chiara, Porcelli, Stefano, Drago, Antonio, Spina, Edoardo, De Ronchi, Diana, Serretti, Alessandro·2011·Frontiers in Pharmacology

DOI 10.3389/fphar.2011.00006PMC PMC3108562

Open this paper in CoChat — free account Open PDF

Abstract

Up to 60% of depressed patients do not respond completely to antidepressants (ADs) and up to 30% do not respond at all. Genetic factors contribute for about 50% of the AD response. During the recent years the possible influence of a set of candidate genes as genetic predictors of AD response efficacy was investigated by us and others. They include the cytochrome P450 superfamily, the P-glycoprotein (ABCB1), the tryptophan hydroxylase, the catechol-O-methyltransferase, the monoamine oxidase A, the serotonin transporter (5-HTTLPR), the norepinephrine transporter, the dopamine transporter, variants in the 5-hydroxytryptamine receptors (5-HT1A, 5-HT2A, 5-HT3A, 5-HT3B, and 5-HT6), adrenoreceptor beta-1 and alpha-2, the dopamine receptors (D2), the G protein beta 3 subunit, the corticotropin releasing hormone receptors (CRHR1 and CRHR2), the glucocorticoid receptors, the c-AMP response-element binding, and the brain-derived neurotrophic factor. Marginal associations were reported for angiotensin I converting enzyme, circadian locomotor output cycles kaput protein, glutamatergic system, nitric oxide synthase, and interleukin 1-beta gene. In conclusion, gene variants seem to influence human behavior, liability to disorders and treatment response. Nonetheless, gene × environment interactions have been hypothesized to modulate several of these effects.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.3389/fphar.2011.00006

Cites

429 of 431 references verified2 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Participants in drug trials often discern from noticeable side effects when they receive active drug rather than placebo.
“Although it is possible in drug trials, participants often discern from noticeable side effects when they receive active drug rather than placebo. 591”
From Time for united action on depression: a Lancet–World Psychiatric Association Commission (2022) · cites this paper as [591]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Two new Later Stone Age sites from the Final Pleistocene in the Falémé Valley, eastern Senegal
Ndiaye, M., Lespez, L., Tribolo, C., Rassé, M., Hadjas, I., Davidoux, S., Huysecom, É., & Douze, K. (2024) · Monash University Research Portal (Monash University) · doi:10.3929/ethz-b-000667478 · Cited by 24,015 · see citing works
Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene
Caspi, A., Sugden, K., Moffitt, T. E., Taylor, A., Craig, I. W., Harrington, H., McClay, J., Mill, J., Martin, J., Braithwaite, A., et al. (2003) · Science · doi:10.1126/science.1083968 · Cited by 8,120 · see citing works
Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study
Murray, C. J. L., & López, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07492-2 · Cited by 7,007 · see citing works
Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 1× · see citing works
“Treatment-resistant depression (TRD) is therefore a common problem in the treatment of major depressive disorder (MDD), with 60–70% of all patients meeting the criteria for TRD (Rush et al., 2006a,b; Trivedi et al., 2006a,b).”
Background
The Endophenotype Concept in Psychiatry: Etymology and Strategic Intentions
Gottesman, I. I., & Gould, T. D. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.4.636 · Cited by 5,615 · see citing works
Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region
Lesch, K.-P., Bengel, D., Heils, A., Sabol, S. Z., Greenberg, B. D., Petri, S., Benjamin, J., Müller, C. R., Hamer, D. H., & Murphy, D. L. (1996) · Science · doi:10.1126/science.274.5292.1527 · Cited by 5,162 · see citing works
The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function
Egan, M. F., Kojima, M., Callicott, J. H., Goldberg, T. E., Kolachana, B. S., Bertolino, A., Zaitsev, E., Gold, B., Goldman, D., Dean, M., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00035-7 · Cited by 3,888 · see citing works
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · see citing works
An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels
Rigat, B., Hubert, C., Alhenc-Gelas, F., Cambien, F., Corvol, P., & Soubrier, F. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114844 · Cited by 3,767 · see citing works
THE CATECHOLAMINE HYPOTHESIS OF AFFECTIVE DISORDERS: A REVIEW OF SUPPORTING EVIDENCE
Schildkraut, J. J. (1965) · American Journal of Psychiatry · doi:10.1176/ajp.122.5.509 · Cited by 3,499 · see citing works
Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.
Thiebaut, F., TSURUO, T., Hamada, H., Gottesman, M. M., PASTAN, I., & Willingham, M. C. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7735 · Cited by 2,777 · see citing works
Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H., Brockmöller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M. F., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3473 · Cited by 2,366 · see citing works
Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
Schinkel, A. H., Smit, J., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., Riele, H. T., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90212-7 · Cited by 2,284 · see citing works
Allelic Variation of Human Serotonin Transporter Gene Expression
Heils, A., Teufel, A., Petri, S., Stöber, G., Riederer, P., Bengel, D., & Lesch, K. P. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66062621.x · Cited by 2,221 · see citing works
Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders
Lachman, H. M., Papolos, D. F., Saito, T., Yu, Y.-M., Szumlanski, C. L., & Weinshilboum, R. M. (1996) · Pharmacogenetics · doi:10.1097/00008571-199606000-00007 · Cited by 1,788 · cited 1× · see citing works
“…COMT gene have several allelic variants, among these the most well-studied is rs4680, results in a change in the enzyme structure [Val(108/158)Met], which influences activity (high activity in Val/Val, intermediate activity in Val/Met, and low activity in Met/Met genotype; (Lachman et al., 1996).”
Background
Synthesis of Serotonin by a Second Tryptophan Hydroxylase Isoform
Walther, D. J., Peter, J., Bashammakh, S., Hörtnagl, H., Voits, M., Fink, H., & Bäder, M. (2003) · Science · doi:10.1126/science.1078197 · Cited by 1,576 · see citing works
Elevated Concentrations of CSF Corticotropin-Releasing Factor-Like Immunoreactivity in Depressed Patients
Nemeroff, C. B., Widerlöv, E., Bissette, G., Walléus, H., Karlsson, I., Eklund, K., Kilts, C. D., Loosen, P. T., & Vale, W. (1984) · Science · doi:10.1126/science.6334362 · Cited by 1,485 · see citing works
Untitled work
Binder (2004) · doi:10.1080/08977190410001723308 · Cited by 1,481 · see citing works
Molecular analysis of mammalian circadian rhythms
Reppert, S. M., & Weaver, D. R. (2001) · Annual Review of Physiology · doi:10.1146/annurev.physiol.63.1.647 · Cited by 1,444 · see citing works
Heterotrimeric C proteins: Organizers of transmembrane signals
Neer, E. J. (1995) · Cell · doi:10.1016/0092-8674(95)90407-7 · Cited by 1,404 · see citing works
Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states
Gold, P. W., & Chrousos, G. P. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001032 · Cited by 1,274 · see citing works
P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.
Schinkel, A. H., Wagenaar, E., Mol, C. A. A. M., & van Deemter, L. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118699 · Cited by 1,265 · see citing works
Cytokines and major depression
Schiepers, O. J. G., Wichers, M. C., & Maes, M. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.11.003 · Cited by 1,235 · see citing works
Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects
Ingelman‐Sundberg, M., Sim, S. C., Gomez, A. V., & Rodríguez‐Antona, C. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.09.004 · Cited by 1,165 · see citing works
The Many Faces of G Protein Signaling
Hamm, H. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.2.669 · Cited by 1,140 · see citing works
Current advances and trends in the treatment of depression
Blier, P., & de Montigny, C. (1994) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(94)90315-8 · Cited by 1,113 · see citing works
A functional polymorphism in the monoamine oxidase A gene promoter
Sabol, S. Z., Hu, S., & Hamer, D. (1998) · Human Genetics · doi:10.1007/s004390050816 · Cited by 1,079 · see citing works
Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors
Männistö, P. T., & Kaakkola, S. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01423-6 · Cited by 1,068 · see citing works
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033 · see citing works
Inheritance and Drug Response
Weinshilboum, R. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020021 · Cited by 1,032 · see citing works
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002 · see citing works
Untranslated regions of mRNAs.
(2002) · Genome biology · doi:10.1186/gb-2002-3-3-reviews0004 · Cited by 987 · see citing works
Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment
Binder, E. B., Salyakina, D., Lichtner, P., Wochnik, G. M., Ising, M., Pütz, B., Papiol, S., Seaman, S., Lucae, S., Kohli, M. A., et al. (2004) · Nature Genetics · doi:10.1038/ng1479 · Cited by 977 · see citing works
Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization.
Ramamoorthy, S., Bauman, A. L., Moore, K. R., Han, H. J., Yang‐Feng, T. L., Chang, A. S., Ganapathy, V., & Blakely, R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.6.2542 · Cited by 880 · see citing works
Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report
Rush, A. J. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.11.1905 · Cited by 879 · see citing works
Inhibition and Induction of Cytochrome P450 and the Clinical Implications
Lin, J. H., & Lu, A. Y. H. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199835050-00003 · Cited by 827 · see citing works
A BDNF autocrine loop in adult sensory neurons prevents cell death
Acheson, A., Conover, J. C., Fandl, J. P., DeChiara, T. M., Russell, M., Thadani, A., Squinto, S. P., Yancopoulos, G. D., & Lindsay, R. M. (1995) · Nature · doi:10.1038/374450a0 · Cited by 765 · see citing works
Functional significance of a C–>A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine
Sachse, C., Brockmöller, J., Bauer, S., & Roots, I. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00898.x · Cited by 751 · see citing works
Impaired Repression at a 5-Hydroxytryptamine 1A Receptor Gene Polymorphism Associated with Major Depression and Suicide
Lemonde, S., Turecki, G., Bakish, D., Du, L., Hrdina, P. D., Bown, C. D., Sequeira, A., Kushwaha, N., Morris, S. J., Basak, A., et al. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-25-08788.2003 · Cited by 733 · see citing works
Association of a human G-protein β3 subunit variant with hypertension
Siffert, W., Rosskopf, D., Siffert, G., Busch, S., Moritz, A., Erbel, R., Sharma, A. M., Ritz, E., Wichmann, H. ‐., Jakobs, K. H., et al. (1998) · Nature Genetics · doi:10.1038/ng0198-45 · Cited by 726 · see citing works
Increased Numbers of Corticotropin-Releasing Hormone Expressing Neurons in the Hypothalamic Paraventricular Nucleus of Depressed Patients
Raadsheer, F. C., Hoogendijk, W. J. G., Stam, F. C., Tilders, F. J. H., & Swaab, D. F. (2008) · Neuroendocrinology · doi:10.1159/000126778 · Cited by 667 · see citing works
Organization of the human serotonin transporter gene
Lesch, K., Balling, U., Groß, J., Strauss, K. M., Wolozin, B. L., Murphy, D. L., & Riederer, P. F. (1994) · Journal of Neural Transmission · doi:10.1007/bf01276434 · Cited by 628 · see citing works
Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine
Smeraldi, E., Zanardi, R., Benedetti, F., Bella, D. D., Pérez, J., & Catalano, M. (1998) · Molecular Psychiatry · doi:10.1038/sj.mp.4000425 · Cited by 614 · see citing works
Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
Hoffmeyer, S. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050585397 · Cited by 599 · see citing works
A CLOCK Polymorphism Associated with Human Diurnal Preference
Katzenberg, D. R., Young, T. B., Finn, L. A., Lin, L., King, D. P., Takahashi, J. S., & Mignot, E. J.-M. (1998) · SLEEP · doi:10.1093/sleep/21.6.569 · Cited by 587 · see citing works
A Gain-of-function Polymorphism in a G-protein Coupling Domain of the Human β1-Adrenergic Receptor
Mason, D. A., Moore, J. D., Green, S. A., & Liggett, S. B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.18.12670 · Cited by 583 · see citing works
Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs
Bertilsson, L., Dahl, M., Dalén, P., & Al‐Shurbaji, A. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01548.x · Cited by 579 · see citing works
Reduced Corticotropin Releasing Factor Binding Sites in the Frontal Cortex of Suicide Victims
Nemeroff, C. B. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800300075009 · Cited by 555 · see citing works
Polymorphism in serotonin transporter gene associated with susceptibility to major depression
Ogilvie, A. D., Battersby, S., Fink, G., Harmar, A. J., Goodwin, G. M., Bubb, V. J., & Smith, C. A. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90079-3 · Cited by 530 · see citing works
Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients
Serretti, A., Kato, M., De Ronchi, D., & Kinoshita, T. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001926 · Cited by 529 · see citing works
Self-citation
cAMP Response Element-Mediated Gene Transcription Is Upregulated by Chronic Antidepressant Treatment
Thome, J., Sakai, N., Shin, K.-H., Steffen, C., Zhang, Y.-J., Impey, S., Storm, D. R., & Duman, R. S. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04030.2000 · Cited by 507 · see citing works
Loss-of-Function Mutation in Tryptophan Hydroxylase-2 Identified in Unipolar Major Depression
Zhang, X., Gainetdinov, R. R., Beaulieu, J.-M., Sotnikova, T. D., Burch, L. H., Williams, R. B., Schwartz, D. A., Krishnan, K. R. R., & Caron, M. G. (2005) · Neuron · doi:10.1016/j.neuron.2004.12.014 · Cited by 473 · see citing works
Variation in the Gene Encoding the Serotonin 2A Receptor Is Associated with Outcome of Antidepressant Treatment
McMahon, F. J., Buervenich, S., Charney, D. S., Lipsky, R. H., Rush, A. J., Wilson, A. F., Sorant, A. J. M., Papanicolaou, G., Laje, G., D, M. F. M., et al. (2006) · The American Journal of Human Genetics · doi:10.1086/503820 · Cited by 473 · see citing works
Untitled work
(2005) · PubMed · Cited by 470 · see citing works
Cytokines as mediators of depression: what can we learn from animal studies?
Dunn, A. J., Swiergiel, A. H., & Beaurepaire, R. D. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.023 · Cited by 459 · see citing works
Modification of 5‐HT neuron properties by sustained administration of the 5‐HT1A agonist gepirone: Electrophysiological studies in the rat brain
Blier, P. U., & de Montigny, C. (1987) · Synapse · doi:10.1002/syn.890010511 · Cited by 426 · see citing works
CYP2D6 and CYP2C19 genotype‐based dose recommendations for antidepressants: a first step towards subpopulation‐specific dosages
Kirchheiner, J., Brøsen, K., Dahl, M., Gram, L. F., Kasper, S. F., Roots, I., Sjöqvist, F., Spina, E., & Brockmöller, J. (2001) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2001.00299.x · Cited by 422 · see citing works
Self-citation
Allelic Variation in the Serotonin Transporter Promoter Affects Onset of Paroxetine Treatment Response in Late-Life Depression
Pollock, B. G. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00132-9 · Cited by 415 · see citing works
Serotonin transporter gene polymorphism and antidepressant response
Kim, D. K., Lim, S., Lee, S., Sohn, S. E., Kim, S., Hahn, C. G., & Carroll, B. J. (2000) · Neuroreport · doi:10.1097/00001756-200001170-00042 · Cited by 399 · see citing works
Presynaptic 5-HT autoreceptors on serotonergic cell bodies and/or dendrites but not terminals are of the 5-HT1A subtype
Vergé, D., Daval, G., Patey, A., GOZLAN, H., Mestikawy, S. E., & Hamon, M. (1985) · European Journal of Pharmacology · doi:10.1016/0014-2999(85)90099-8 · Cited by 385 · see citing works
Cloning, Characterization, and Chromosomal Localization of a Human 5‐HT6 Serotonin Receptor
Kohen, R., Metcalf, M. A., Khan, N. A., Druck, T., Huebner, K., Lachowicz, J. E., Meltzer, H. Y., Sibley, D. R., Roth, B. L., & Hamblin, M. W. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66010047.x · Cited by 377 · see citing works
A serotonin transporter gene intron 2 polymorphic region, correlated with affective disorders, has allele-dependent differential enhancer-like properties in the mouse embryo
MacKenzie, A., & Quinn, J. P. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.15251 · Cited by 374 · see citing works
The Role of CREB in Depression and Antidepressant Treatment
Blendy, J. A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.11.003 · Cited by 365 · see citing works
Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: An update
Spina, E., Santoro, V., & D’Arrigo, C. (2008) · Clinical Therapeutics · doi:10.1016/s0149-2918(08)80047-1 · Cited by 362 · see citing works
Self-citation
Genome-Wide Pharmacogenetics of Antidepressant Response in the GENDEP Project
Uher, R., Perroud, N. A., Ng, M., Hauser, J., Henigsberg, N., Maier, W., Mors, O. N., Placentino, A., Rietschel, M., Souery, D., et al. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09070932 · Cited by 350 · see citing works
Abnormal behavioral phenotypes of serotonin transporter knockout mice: parallels with human anxiety and depression
Holmes, A., Murphy, D. L., & Crawley, J. N. (2003) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.09.003 · Cited by 342 · see citing works
The Australian Burden of Disease Study: measuring the loss of health from diseases, injuries and risk factors
Mathers, C. D., Stevenson, C., Vos, E. T., & Begg, S. J. (2000) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2000.tb124125.x · Cited by 339 · see citing works
Efficacy of antidepressants in adults
Moncrieff, J., & Kirsch, I. (2005) · BMJ · doi:10.1136/bmj.331.7509.155 · Cited by 329 · see citing works
Polymorphisms of the Glucocorticoid Receptor Gene and Major Depression
van Rossum, E. F. C., Binder, E. B., Majer, M., Koper, J. W., Ising, M., Modell, S., Salyakina, D., Lamberts, S. W. J., & Holsboer, F. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.007 · Cited by 324 · see citing works
Influence of CLOCK gene polymorphism on circadian mood fluctuation and illness recurrence in bipolar depression
Benedetti, F., Serretti, A., Colombo, C., Barbini, B., Lorenzi, C., Campori, E., & Smeraldi, E. (2003) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.20038 · Cited by 324 · see citing works
Self-citation
Mice Lacking the Serotonin Transporter Exhibit 5-HT1A Receptor-Mediated Abnormalities in Tests for Anxiety-like Behavior
Holmes, A., Yang, R. J., Lesch, K., Crawley, J. N., & Murphy, D. L. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300266 · Cited by 312 · see citing works
Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features
Anisman, H., Ravindran, A. V., Griffiths, J., & Merali, Z. (1999) · Molecular Psychiatry · doi:10.1038/sj.mp.4000436 · Cited by 310 · see citing works
Efficacy of Paroxetine in Depression Is Influenced by a Functional Polymorphism Within the Promoter of the Serotonin Transporter Gene
Zanardi, R., Benedetti, F., Bella, D. D., Catalano, M., & Smeraldi, E. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200002000-00021 · Cited by 309 · see citing works
(-)-Propranolol blocks the inhibition of serotonergic dorsal raphe cell firing by 5-HT1A selective agonists
Sprouse, J. S., & Aghajanian, G. K. (1986) · European Journal of Pharmacology · doi:10.1016/0014-2999(86)90782-x · Cited by 306 · see citing works
A Genomewide Association Study Points to Multiple Loci That Predict Antidepressant Drug Treatment Outcome in Depression
Ising, M., Lucae, S., Binder, E. B., Bettecken, T., Uhr, M., Ripke, S., Kohli, M. A., Hennings, J. M., Horstmann, S., Kloiber, S. M., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.95 · Cited by 306 · see citing works
Signaling Pathways Regulating Gene Expression, Neuroplasticity, and Neurotrophic Mechanisms in the Action of Antidepressants: A Critical Overview
Tardito, D., Perez, J., Tiraboschi, E., Musazzi, L., Racagni, G., & Popoli, M. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.1.7 · Cited by 303 · see citing works
Meta‐analysis of the association of a functional serotonin transporter promoter polymorphism with alcohol dependence
Feinn, R., Nellissery, M. J., & Kranzler, H. R. (2005) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30132 · Cited by 300 · see citing works
Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment
Pérez, V., Gilaberte, I., Faries, D. E., Álvarez, E., & Artigas, F. (1997) · The Lancet · doi:10.1016/s0140-6736(96)08007-5 · Cited by 300 · see citing works
Pharmacogenetics of Psychotropic Drug Response
Malhotra, A. K., Murphy, G. M., & Kennedy, J. L. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.780 · Cited by 298 · see citing works
The genetic basis of variability in drug responses
Roden, D. M., & George, A. L. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd705 · Cited by 293 · see citing works
Pathophysiology of depression and mechanisms of treatment
Brigitta, B. (2002) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2002.4.1/bbondy · Cited by 286 · see citing works
10-hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes*
Dalén, P., Dahl, M., Ruiz, M. L. B., Nordin, J., & Bertilsson, L. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90040-6 · Cited by 285 · see citing works
Pharmacogenetics of Antidepressant Medication Intolerance
Murphy, G. M., Kremer, C. M. E., Rodrigues, H. E., & Schatzberg, A. F. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.10.1830 · Cited by 284 · see citing works
Effects of the Serotonin Transporter Gene Promoter Polymorphism onMirtazapine and Paroxetine Efficacy and Adverse Events in Geriatric MajorDepression
Murphy, G. M., Hollander, S. B., Rodrigues, H. E., Kremer, C. M. E., & Schatzberg, A. F. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1163 · Cited by 275 · see citing works
5-HT1A Receptors, Gene Repression, and Depression: Guilt by Association
Albert, P. R., & Lemonde, S. (2004) · The Neuroscientist · doi:10.1177/1073858404267382 · Cited by 275 · see citing works
The combined dexamethasone/CRH test as a potential surrogate marker in depression
Ising, M., Kunzel, H. E., Binder, E. B., Nickel, T., Modell, S., & Holsboer, F. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.03.014 · Cited by 268 · see citing works
Genetic dissection of psychopathological symptoms: Insomnia in mood disorders and CLOCK gene polymorphism
Serretti, A., Benedetti, F., Mandelli, L., Lorenzi, C., Pirovano, A., Colombo, C., & Smeraldi, E. (2003) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.20053 · Cited by 264 · see citing works
Self-citation
Association between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in women
Yeo, A., Boyd, P., Lumsden, S., Saunders, T., Handley, A., Stubbins, M., Knaggs, A., Asquith, S., Taylor, I., Bahari, B., et al. (2004) · Gut · doi:10.1136/gut.2003.035451 · Cited by 260 · see citing works
Basic psychopharmacology of antidepressants, part 1: Antidepressants have seven distinct mechanisms of action.
Stahl, S. M. (1998) · PubMed · Cited by 260 · see citing works
Monoamine depletion in psychiatric and healthy populations: review
Booij, L., van der Does, A., & Riedel, W. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001423 · Cited by 259 · see citing works
A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter
Spurlock, G., Heils, A., Holmans, P., Williams, J. H., D’Souza, U. M., Cardno, A. G., Murphy, K. C., Jones, L. A., Buckland, P. R., McGuffin, P., et al. (1998) · Molecular Psychiatry · doi:10.1038/sj.mp.4000342 · Cited by 254 · see citing works
Demonstration of the Efficacy and Safety of a Novel Substance P (NK1) Receptor Antagonist in Major Depression
Kramer, M. S., Winokur, A., Kelsey, J. E., Preskorn, S., Rothschild, A. J., Snavely, D. B., Ghosh, K., Ball, W. A., Reines, S. A., Munjack, D. J., et al. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300260 · Cited by 254 · see citing works
A 6-Week Randomized, Placebo-Controlled Trial of CP-316,311 (a Selective CRH 1 Antagonist) in the Treatment of Major Depression
Binneman, B., Feltner, D., Kolluri, S., Shi, Y., Qiu, R., & Stiger, T. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07071199 · Cited by 254 · see citing works
Molecular Basis of Sickness Behaviora
DANTZER, R., BLUTHÉ, R., GHEUSI, G., CREMONA, S., LAYÉ, S., PARNET, P., & KELLEY, K. W. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb08321.x · Cited by 249 · see citing works
CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine
Shams, M. E. E., Arneth, B. M., Hiemke, C., Dragicevic, A., Muller, M. J., Kaiser, R., Lackner, K. J., & Härtter, S. (2006) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2006.00763.x · Cited by 248 · see citing works
Penetration of Amitriptyline, but Not of Fluoxetine, into Brain is Enhanced in Mice with Blood-Brain Barrier Deficiency Due to Mdr1a P-Glycoprotein Gene Disruption
Uhr, M. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00095-0 · Cited by 245 · see citing works
Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene
Williams, J. H., Spurlock, G., McGuffin, P., Owen, M., Mallet, J. J., Nöthen, M. M., Gill, M., Aschauer, H. N., Nylander, P.-O., & Macciardi, F. M. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90939-3 · Cited by 245 · see citing works
How can drug discovery for psychiatric disorders be improved?
Agid, Y., Buzsáki, G., Diamond, D. M., Frackowiak, R., Giedd, J., Girault, J.-A., Grace, A., Lambert, J. J., Manji, H., Mayberg, H., et al. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2217 · Cited by 240 · see citing works
Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population
Gaikovitch, E. A., Cascorbi, I., Mrozikiewicz, P. M., ller, J. R. B., Fr�tschl, R., K�pke, K., Gerloff, T., Chernov, J., & Roots, I. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0606-2 · Cited by 237 · see citing works
The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications
Brady, L. S., Gold, P. W., Herkenham, M. A., Lynn, A. B., & Whitfield, H. J. (1992) · Brain Research · doi:10.1016/0006-8993(92)90459-m · Cited by 236 · see citing works
Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects
Ito, S., Ieiri, I., Tanabe, M., Suzuki, A., Higuchi, S., & Otsubo, K. (2001) · Pharmacogenetics · doi:10.1097/00008571-200103000-00008 · Cited by 234 · see citing works
Investigation of serotonin-related genes in antidepressant response
Peters, E. J., Slager, S. L., McGrath, P. J., Knowles, J. A., & Hamilton, S. P. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001502 · Cited by 231 · see citing works
Impact of the Ultrarapid CYP2C19*17 Allele on Serum Concentration of Escitalopram in Psychiatric Patients
Rudberg, I., Mohebi, B. U., Hermann, M., Refsum, H., & Molden, E. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100291 · Cited by 231 · see citing works
The Effect of Paroxetine on 5-HT2A Receptors in Depression: An [18F]Setoperone PET Imaging Study
Meyer, J. H., Kapur, S., Eisfeld, B., Brown, G. M., Houle, S., DaSilva, J., Wilson, A. A., Rafi-Tari, S., Mayberg, H. S., & Kennedy, S. H. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.1.78 · Cited by 231 · see citing works
Receptor reserve for 5-hydroxytryptamine1A-mediated inhibition of serotonin synthesis: possible relationship to anxiolytic properties of 5-hydroxytryptamine1A agonists.
Meller, E., Goldstein, M., & Bohmaker, K. (1990) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09962-6 · Cited by 231 · see citing works
Higher 5-HT1A Receptor Binding Potential During a Major Depressive Episode Predicts Poor Treatment Response: Preliminary Data from a Naturalistic Study
Parsey, R. V., Olvet, D. M., Oquendo, M. A., Huang, Y., Ogden, R. T., & Mann, J. J. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300992 · Cited by 227 · see citing works
Genetic predictors of response to antidepressants in the GENDEP project
Uher, R., Huezo-Diaz, P., Perroud, N., Smith, R., Rietschel, M., Mors, O., Hauser, J., Maier, W., Kozel, D., Henigsberg, N., et al. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.12 · Cited by 226 · see citing works
Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients
Yoshida, K., Ito, K., Sato, K., Takahashi, H., Kamata, M., Higuchi, H., Shimizu, T., Itoh, K., Inoue, K., Tezuka, T., et al. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00287-1 · Cited by 226 · see citing works
Serotonin transporter promoter and intron 2 polymorphisms: relationship between allelic variants and gene expression
Hranilovic, D., Stefulj, J., Schwab, S., Borrmann-Hassenbach, M., Albus, M., Jernej, B., & Wildenauer, D. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.01.029 · Cited by 224 · see citing works
Sequence Analysis of the Serotonin Transporter and Associations with Antidepressant Response
Kraft, J. B., Slager, S. L., McGrath, P. J., & Hamilton, S. P. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.048 · Cited by 224 · see citing works
Serotonin Transporter Gene Variants and Behavior: A Comprehensive Review
Serretti, A., Calati, R., Mandelli, L., & Ronchi, D. D. (2006) · Current Drug Targets · doi:10.2174/138945006779025419 · Cited by 222 · see citing works
Self-citation
Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-httlpr in delusional and nondelusional depression
Zanardi, R., Serretti, A., Rossini, D., Franchini, L., Cusin, C., Lattuada, E., Dotoli, D., & Smeraldi, E. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01118-0 · Cited by 219 · see citing works
Self-citation
Association Between a Functional Serotonin Transporter Promoter Polymorphism and Citalopram Treatment in Adult Outpatients With Major Depression
Hu, X., Rush, A. J., Charney, D. S., Wilson, A. F., Sorant, A. J. M., Papanicolaou, G., D, M. F. M., Trivedi, M. H., Wisniewski, S. R., Laje, G., et al. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.7.783 · Cited by 218 · see citing works
Increased 5-HT 2A Receptor Binding in Euthymic, Medication-Free Patients Recovered From Depression: A Positron Emission Study With [ 11 C]MDL 100,907
Bhagwagar, Z., Hinz, R., Taylor, M. J., Fancy, S., Cowen, P. J., & Grasby, P. M. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1580 · Cited by 214 · see citing works
Association study of a brain‐derived neurotrophic‐factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response
Tsai, S., Cheng, C., Yu, Y. W., Chen, T., & Hong, C. (2003) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.20026 · Cited by 213 · see citing works
Genetic Markers of Suicidal Ideation Emerging During Citalopram Treatment of Major Depression
Laje, G., Paddock, S., Manji, H. K., Rush, A. J., Wilson, A. F., Charney, D. S., & McMahon, F. J. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06122018 · Cited by 213 · see citing works
Association of the C(–1019)G 5-HT1A functional promoter polymorphism with antidepressant response
Lemonde, S., Du, L., Bakish, D., Hrdina, P. D., & Albert, P. R. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004699 · Cited by 212 · see citing works
Effect of the 5-HT1A receptor agonist 8-OH-DPAT on the release of 5-HT in dorsal and median raphe-innervated rat brain regions as measured by in vivo microdialysis
Hjorth, S., & Sharp, T. (1991) · Life Sciences · doi:10.1016/0024-3205(91)90216-x · Cited by 211 · see citing works
Identifying a series of candidate genes for mania and psychosis: a convergent functional genomics approach
Niculescu, A. B., Segal, D. S., Kuczenski, R. T., Barrett, T. B., Hauger, R. L., & Kelsoe, J. R. (2000) · Physiological Genomics · doi:10.1152/physiolgenomics.2000.4.1.83 · Cited by 206 · see citing works
Region-specific transcriptional changes following the three antidepressant treatments electro convulsive therapy, sleep deprivation and fluoxetine
Conti, B., Maier, R., Barr, A. M., Morale, M. C., Lu, X., Sanna, P. P., Bilbe, G., Hoyer, D., & Bartfai, T. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001897 · Cited by 205 · see citing works
Monoamine Transporter Gene Polymorphisms and Antidepressant Response in Koreans With Late-Life Depression
Kim, H. R., Lim, S., Kim, S., Kim, J., Chang, Y. H., Carroll, B. J., & Kim, D. K. (2006) · JAMA · doi:10.1001/jama.296.13.1609 · Cited by 202 · see citing works
A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression
Roberts, R. L., Joyce, P. R., Mulder, R., Begg, E., & Kennedy, M. A. (2002) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500099 · Cited by 201 · see citing works
Hippocampal 5-HT synthesis and release in vivo is decreased by infusion of 8-OHDPAT into the nucleus raphe dorsalis
Hutson, P. H., Sarna, G. S., O’Connell, M. T., & Curzon, G. (1989) · Neuroscience Letters · doi:10.1016/0304-3940(89)90698-8 · Cited by 199 · see citing works
Cyp2d6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants—a pilot study
Rau, T. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.12.015 · Cited by 198 · see citing works
Evidence for an association between a G-protein β3-gene variant with depression and response to antidepressant treatment
Zill, P., Baghai, T. C., Zwanzger, P., Schüle, C., Minov, C., Riedel, M. J., Neumeier, K., Rupprecht, R., & Bondy, B. (2000) · Neuroreport · doi:10.1097/00001756-200006260-00018 · Cited by 197 · see citing works
Analysis of tryptophan hydroxylase I and II mRNA expression in the human brain: A post-mortem study
Zill, P., Büttner, A., Eisenmenger, W., MOLLER, H., Ackenheil, M., & Bondy, B. (2005) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2005.05.004 · Cited by 196 · see citing works
Initial conditions of serotonin transporter kinetics and genotype: influence on ssri treatment trial outcome
Rausch, J. L., Johnson, M. E., Fei, Y.-J., Li, J. Q., Shendarkar, N., Hobby, H. M., Ganapathy, V., & Leibach, F. H. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01283-5 · Cited by 193 · see citing works
The Interleukin 1 Beta (IL1B) Gene Is Associated with Failure to Achieve Remission and Impaired Emotion Processing in Major Depression
Baune, B. T., Dannlowski, U., Domschke, K., Janssen, D. G. A., Jordan, M. A., Ohrmann, P., Bauer, J., Biroš, E., Arolt, V., Kugel, H., et al. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.11.004 · Cited by 193 · see citing works
Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine
Br�sen, K., Hansen, J. G., Nielsen, K. K., Sindrup, S. H., & Gram, L. F. (1993) · European Journal of Clinical Pharmacology · doi:10.1007/bf00316471 · Cited by 193 · see citing works
Cellular and molecular mechanisms in the long-term action of antidepressants.
Racagni, G., & Popoli, M. (2008) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2008.10.4/gracagni · Cited by 192 · see citing works
Association of GRIK4 With Outcome of Antidepressant Treatment in the STAR*D Cohort
Paddock, S., Laje, G., Charney, D. S., Rush, A. J., Wilson, A. F., Sorant, A. J. M., Lipsky, R. H., Wisniewski, S. R., Manji, H., & McMahon, F. J. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06111790 · Cited by 192 · see citing works
Important messages in the ‘post’: recent discoveries in 5-HT neurone feedback control
Sharp, T., Boothman, L. J., Raley, J., & Quérée, P. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.10.009 · Cited by 190 · see citing works
Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder
Hong, C.-J., Chen, T., Yu, Y. W.-Y., & Tsai, S.-J. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500340 · Cited by 189 · see citing works
Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression
Minov, C., Baghai, T. C., Schüle, C., Zwanzger, P., Schwarz, M., Zill, P., Rupprecht, R., & Bondy, B. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01704-9 · Cited by 189 · see citing works
Molecular genetic studies of ADHD: 1991 to 2004
Bobb, A. J., Castellanos, F. X., Addington, A. M., & Rapoport, J. L. (2004) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30086 · Cited by 188 · see citing works
Corelease of Dopamine and Serotonin from Striatal Dopamine Terminals
Zhou, F.-M., Liang, Y., Salas, R., Zhang, L., Biasi, M. D., & Dani, J. A. (2005) · Neuron · doi:10.1016/j.neuron.2005.02.010 · Cited by 187 · see citing works
Inhibition of neurons in the amygdala by dorsal raphe stimulation: Mediation through a direct serotonergic pathway
Wang, R. Y., & Aghajanian, G. K. (1977) · Brain Research · doi:10.1016/0006-8993(77)90499-1 · Cited by 186 · see citing works
Polymorphisms in GRIK4, HTR2A, and FKBP5 Show Interactive Effects in Predicting Remission to Antidepressant Treatment
Horstmann, S., Lucae, S., Menke, A., Hennings, J. M., Ising, M., Roeske, D., Müller-Myhsok, B., Holsboer, F., & Binder, E. B. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.180 · Cited by 185 · see citing works
Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: Association with major depression and antidepressant response in Mexican-Americans
Dong, C., Wong, M.-L., & Licinio, J. (2009) · Molecular Psychiatry · doi:10.1038/mp.2009.92 · Cited by 182 · see citing works
Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment
Papiol, S., Arias, B., Gastó, C., Gutiérrez, B., Catalán, R., & Fañanás, L. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.02.017 · Cited by 181 · see citing works
Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder
Choi, M.-J., Kang, R.-H., Lim, S.-W., Oh, K., & Lee, M. (2006) · Brain Research · doi:10.1016/j.brainres.2006.08.012 · Cited by 180 · see citing works
How can we realize the promise of personalized antidepressant medicines?
Holsboer, F. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2453 · Cited by 177 · see citing works
Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment
Perlis, R. H., Mischoulon, D., Smoller, J. W., Wan, Y. Y., Lamon‐Fava, S., Lin, K.-M., Rosenbaum, J. F., & D, M. F. M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00424-4 · Cited by 177 · see citing works
The effect of escitalopram, desipramine, electroconvulsive seizures and lithium on brain-derived neurotrophic factor mRNA and protein expression in the rat brain and the correlation to 5-HT and 5-HIAA levels
Jacobsen, J. P. R., & Mørk, A. (2004) · Brain Research · doi:10.1016/j.brainres.2004.07.065 · Cited by 177 · see citing works
Association between depressive behavior and absence of serotonin-dopamine interaction in the nucleus accumbens
Zangen, A., Nakash, R., Overstreet, D. H., & Yadid, G. (2001) · Psychopharmacology · doi:10.1007/s002130100746 · Cited by 177 · see citing works
Novel Sequence Variations in the Brain-Derived Neurotrophic Factor Gene and Association With Major Depression and Antidepressant Treatment Response
Licinio, J., Dong, C., & Wong, M. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.38 · Cited by 176 · see citing works
P-Glycoprotein gene (MDR1) cDNA from human adrenal: Normal P-glycoprotein carries Gly185 with an altered pattern of multidrug resistance
Kioka, N., Tsubota, J., Kakehi, Y., Komano, T., Gottesman, M. M., PASTAN, I., & Ueda, K. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)91985-2 · Cited by 175 · see citing works
5-HTTLPR Polymorphism of the Serotonin Transporter Gene Predicts Non-Remission in Major Depression Patients Treated With Citalopram in a 12-Weeks Follow Up Study
Arias, B., Catalán, R., Gastó, C., Gutiérrez, B., & Fañanás, L. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000095350.32154.73 · Cited by 174 · see citing works
ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder
Kato, M., Fukuda, T., Serretti, A., Wakeno, M., Okugawa, G., Ikenaga, Y., Hosoi, Y., Takekita, Y., Mandelli, L., Azuma, J., et al. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.09.003 · Cited by 174 · see citing works
Self-citation
Association between violent suicidal behavior and the low activity allele of the serotonin transporter gene
Courtet, P., Baud, P., Abbar, M., Boulenger, J.-P., Castelnau, D., Mouthon, D., Malafosse, A., & Burési, C. (2001) · Molecular Psychiatry · doi:10.1038/sj.mp.4000856 · Cited by 169 · see citing works
Dopaminergic mechanism of antidepressant action in depressed patients
Willner, P., Hale, A. S., & Argyropoulos, S. (2005) · Journal of Affective Disorders · doi:10.1016/j.jad.2004.12.010 · Cited by 169 · see citing works
Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans
Licinio, J., O'Kirwan, F., Irizarry, K. J. L., Merriman, B., Thakur, S., Jepson, R., Lake, S. L., Tantisira, K. G., Weiss, S. T., & Wong, M. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001587 · Cited by 168 · see citing works
Association of GRIK4 With Outcome of Antidepressant Treatment in the STAR*D Cohort
Ballenger, J. C. (2009) · Yearbook of Psychiatry and Applied Mental Health · doi:10.1016/s0084-3970(08)79086-8 · Cited by 167 · see citing works
Effects of the Serotonin Type 2A, 3A and 3B Receptor and the Serotonin Transporter Genes on Paroxetine and Fluvoxamine Efficacy and Adverse Drug Reactions in Depressed Japanese Patients
Kato, M., Fukuda, T., Wakeno, M., Fukuda, K., Okugawa, G., Ikenaga, Y., Yamashita, M., Takekita, Y., Nobuhara, K., Azuma, J., et al. (2006) · Neuropsychobiology · doi:10.1159/000094727 · Cited by 166 · see citing works
Insomnia improvement during antidepressant treatment andCLOCK gene polymorphism
Serretti, A., Cusin, C., Benedetti, F., Mandelli, L., Pirovano, A., Zanardi, R., Colombo, C., & Smeraldi, E. (2005) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30130 · Cited by 164 · see citing works
Self-citation
Differential regulation of serotonin (5-HT) release in the striatum and hippocampus by 5-HT1A autoreceptors of the dorsal and median raphe nuclei.
Kreiss, D. S., & Lucki, I. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38872-5 · Cited by 164 · see citing works
Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity
Serretti, A., Zanardi, R., Rossini, D., Cusin, C., Lilli, R., & Smeraldi, E. (2001) · Molecular Psychiatry · doi:10.1038/sj.mp.4000876 · Cited by 162 · see citing works
Self-citation
The Mouse Clock Mutation Behaves as an Antimorph and Maps Within the W19H Deletion, Distal of Kit
King, D. P., Vitaterna, M. H., Chang, A., Dove, W. F., Pinto, L. H., Turek, F. W., & Takahashi, J. S. (1997) · Genetics · doi:10.1093/genetics/146.3.1049 · Cited by 162 · see citing works
Genetic Polymorphism in MDR-1: A Tool for Examining Allelic Expression in Normal Cells, Unselected and Drug-Selected Cell Lines, and Human Tumors
Mickley, L. A., Lee, J., Weng, Z., Zhan, Z., Alvarez, M. G., Wilson, W. H., Bates, S. E., & Fojo, T. (1998) · Blood · doi:10.1182/blood.v91.5.1749 · Cited by 162 · see citing works
HTR2A Gene Variants and Psychiatric Disorders: A Review of Current Literature and Selection of SNPs for Future Studies
Drago, A., & Ronchi, D. D. (2007) · Current Medicinal Chemistry · doi:10.2174/092986707781368450 · Cited by 162 · see citing works
Self-citation
Changes in Human In vivo Serotonin and Dopamine Transporter Availabilities during Chronic Antidepressant Administration
Kugaya, A., Seneca, N. M., Snyder, P. J., Williams, S. A., Malison, R. T., Baldwin, R. M., Seibyl, J. P., & Innis, R. B. (2002) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300036 · Cited by 161 · see citing works
Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting
Grasm�der, K., Verwohlt, P. L., Rietschel, M., Dragičević, A., M�ller, M., Hiemke, C., Freymann, N., Zobel, A. W., Maier, W., & Rao, M. (2004) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-004-0766-8 · Cited by 161 · see citing works
Biochemical and Behavioral Evidence for Antidepressant-Like Effects of 5-HT6Receptor Stimulation
Svenningsson, P., Tzavara, E. T., Qi, H., Carruthers, R., Witkin, J. M., Nomikos, G. G., & Greengard, P. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.3110-06.2007 · Cited by 160 · see citing works
Sequence, splice site and population frequency distribution analyses of the polymorphic human tryptophan hydroxylase intron 7
Nielsen, D. A., Jenkins, G. L., Stefanisko, K. M., Jefferson, K. K., & Goldman, D. A. (1997) · Molecular Brain Research · doi:10.1016/s0169-328x(96)00304-x · Cited by 160 · see citing works
Prediction of Antidepressant Response to Milnacipran by Norepinephrine Transporter Gene Polymorphisms
Yoshida, K., Takahashi, H., Higuchi, H., Kamata, M., Ito, K., Sato, K., Naito, S., Shimizu, T., Itoh, K., Inoue, K., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.9.1575 · Cited by 160 · see citing works
Association between the TPH gene A218C polymorphism and suicidal behavior: A meta‐analysis
Bellivier, F., Chaste, P., & Malafosse, A. (2003) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.20015 · Cited by 159 · see citing works
CYP2D6 and ABCB1 Genetic Variability: Influence on Paroxetine Plasma Level and Therapeutic Response
Gex‐Fabry, M., Eap, C. B., Oneda, B., Gervasoni, N., Aubry, J., Bondolfi, G., & Bertschy, G. (2008) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31817d6f5d · Cited by 157 · see citing works
Pharmacokinetic Genes Do Not Influence Response or Tolerance to Citalopram in the STAR*D Sample
Peters, E. J., Slager, S. L., Kraft, J. B., Jenkins, G. D., Reinalda, M. S., McGrath, P. J., & Hamilton, S. P. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001872 · Cited by 157 · see citing works
Variations in the 5-Hydroxytryptamine Type 3B Receptor Gene as Predictors of the Efficacy of Antiemetic Treatment in Cancer Patients
Tremblay, P., Kaiser, R., Sezer, O., Rösler, N., Schelenz, C., Possinger, K., Roots, I., & Brockmöller, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.164 · Cited by 157 · see citing works
5-HT 6 receptor antagonists enhance retention of a water maze task in the rat
Rogers, D., & Hagan, J. J. (2001) · Psychopharmacology · doi:10.1007/s002130100840 · Cited by 155 · see citing works
Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression
Wesołowska, A., & Nikiforuk, A. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.01.007 · Cited by 154 · see citing works
Local, but not systemic, administration of serotonergic antidepressants decreases hippocampal nitric oxide synthase activity
Wegener, G., Volke, V., Harvey, B. H., & Rosenberg, R. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03738-1 · Cited by 151 · see citing works
Analysis of Association Between the Serotonin Transporter and Antidepressant Response in a Large Clinical Sample
Kraft, J. B., Peters, E. J., Slager, S. L., Jenkins, G. D., Reinalda, M. S., McGrath, P. J., & Hamilton, S. P. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.07.017 · Cited by 150 · see citing works
Association Study of the Interleukin-1beta (C-511T) Genetic Polymorphism with Major Depressive Disorder, Associated Symptomatology, and Antidepressant Response
Yu, Y. W. ‐., Chen, T., Hong, C., Chen, H.-M., & Tsai, S. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300172 · Cited by 150 · see citing works
Moderation of antidepressant response by the serotonin transporter gene
Huezo-Diaz, P., Uher, R., Smith, R. G., Rietschel, M., Henigsberg, N., Marušiˇ, A., Mors, O. N., Maier, W., Hauser, J., Souery, D., et al. (2009) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.108.062521 · Cited by 150 · see citing works
The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression
Szegedi, A., Rujescu, D., Tadić, A., Müller, M., Kohnen, R., Stassen, H. H., & Dahmen, N. (2004) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500289 · Cited by 149 · see citing works
The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder
Durham, L. K., Webb, S., Milos, P. M., Clary, C., & Seymour, A. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1562-3 · Cited by 149 · see citing works
Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders
Liu, Z., Zhu, F., Wang, G., Xiao, Z., Tang, J., Liu, W., Wang, H., Liu, H., Wang, X., Ying-liang, W., et al. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.12.013 · Cited by 148 · see citing works
Association Between Treatment-Emergent Suicidal Ideation With Citalopram and Polymorphisms Near Cyclic Adenosine Monophosphate Response Element Binding Protein in the STAR*D Study
Perlis, R. H., Purcell, S., D, M. F. M., Fagerness, J. A., Rush, A. J., Trivedi, M. H., & Smoller, J. W. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.6.689 · Cited by 148 · see citing works
Decrease in Brain Serotonin 2 Receptor Binding in Patients With Major Depression Following Desipramine Treatment
Yatham, L. N., Liddle, P. F., Dennie, J., Shiah, I., Adam, M. J., Lane, C. J., Lam, R. W. M., & Ruth, T. J. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.8.705 · Cited by 147 · see citing works
Prevalence and outcome of partial remission in depression
Tranter, R., O’Donovan, C., Chandarana, P. C., & Kennedy, S. H. (2002) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0242 · Cited by 145 · see citing works
Association of the COMT val158met Variant with Antidepressant Treatment Response in Major Depression
Baune, B. T., Hohoff, C., Berger, K., Neumann, A., Mortensen, S., Roehrs, T., Deckert, J., Arolt, V., & Domschke, K. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301462 · Cited by 145 · see citing works
Interaction between serotonin transporter gene, catechol-O-methyltransferase gene and stressful life events in mood disorders
Mandelli, L., Serretti, A., Marino, E., Pirovano, A., Calati, R., & Colombo, C. (2006) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145706006882 · Cited by 145 · see citing works
Self-citation
Allele-Specific Change of Concentration and Functional Gene Dose for the Prediction of Steady-State Serum Concentrations of Amitriptyline and Nortriptyline in CYP2C19 and CYP2D6 Extensive and Intermediate Metabolizers
Steimer, W., Zöpf, K., von Amelunxen, S., Pfeiffer, H., Bachofer, J., Popp, J., Meßner, B., Kissling, W., & Leucht, S. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2003.030825 · Cited by 141 · see citing works
An insertion/deletion polymorphism in the angiotensin converting enzyme gene is associated with both brain substance P contents and affective disorders
Arinami, T., Li, L., Mitsushio, H., Itokawa, M., Hamaguchi, H., & Toru, M. (1996) · Biological Psychiatry · doi:10.1016/s0006-3223(95)00597-8 · Cited by 140 · see citing works
Serotonin transporter gene polymorphisms are associated with anxiety‐related personality traits in women
Melke, J., Landén, M., Baghei, F., Rosmond, R., Holm, G., Björntorp, P. A., Westberg, L., Hellstrand, M., & Eriksson, E. (2001) · American Journal of Medical Genetics · doi:10.1002/ajmg.1434 · Cited by 139 · see citing works
Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram
Brøsen, K., & Naranjo, C. A. (2001) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(01)00101-8 · Cited by 139 · see citing works
A 40-nucleotide repeat polymorphism in the human dopamine transporter gene
Sano, A., Kondoh, K., Kakimoto, Y., & Kondo, I. (1993) · Human Genetics · doi:10.1007/bf00217369 · Cited by 139 · see citing works
The Evolution of Drug Metabolism
Nebert, D., & Dieter, M. Z. (2000) · Pharmacology · doi:10.1159/000028393 · Cited by 138 · see citing works
Venlafaxine Serum Levels and CYP2D6 Genotype
Veefkind, A. H., Haffmans, P. M. J., & Hoencamp, E. (2000) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200004000-00011 · Cited by 136 · see citing works
SLC6A4 variation and citalopram response
Mrazek, D. A., Rush, A. J., Biernacka, J. M., O’Kane, D. J., Cunningham, J. M., Wieben, E. D., Schaid, D. J., Drews, M. S., Courson, V. L., Snyder, K. A., et al. (2008) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30816 · Cited by 136 · see citing works
Association between the 5′ UTR variant C178T of the serotonin receptor gene HTR3A and bipolar affective disorder
Niesler, B., Flohr, T., Nöthen, M. M., Fischer, C., Rietschel, M., Franzek, E., Albus, M., Propping, P., & Rappold, G. (2001) · Pharmacogenetics · doi:10.1097/00008571-200108000-00002 · Cited by 131 · see citing works
Chromosomal organization of adrenergic receptor genes.
Yang‐Feng, T. L., Xue, F. Y., Zhong, W., Cotecchia, S., Frielle, T., Caron, M. G., Lefkowitz, R. J., & Francke, U. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.4.1516 · Cited by 131 · see citing works
The C(–1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings
Serretti, A., Artioli, P., Lorenzi, C., Pirovano, A., Tubazio, V., & Zanardi, R. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004687 · Cited by 131 · see citing works
Self-citation
Molecular genetics of the human cytochrome P450 monooxygenase superfamily
Smith, G. C., Stubbins, M. J., Harries, L. W., & Wolf, C. R. (1998) · Xenobiotica · doi:10.1080/004982598238868 · Cited by 130 · see citing works
THE PHARMACOLOGICAL ROLE OF P-GLYCOPROTEIN IN THE INTESTINAL EPITHELIUM
van Asperen, J., van Tellingen, O., & Beijnen, J. H. (1998) · Pharmacological Research · doi:10.1006/phrs.1998.0326 · Cited by 130 · see citing works
Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: A pilot study
Nikisch, G., Eap, C. B., & Baumann, P. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.09.010 · Cited by 125 · see citing works
Tryptophan hydroxylase and catechol-O-methyltransferase gene polymorphisms: relationships to monoamine metabolite concentrations in CSF of healthy volunteers
Jönsson, E. G., Goldman, D. A., Spurlock, G., Gustavsson, P. J., Nielsen, D. A., Linnoila, M., Owen, M. J., & Sedvall, G. C. (1997) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02922258 · Cited by 125 · see citing works
Tissue‐specific expression of tryptophan hydroxylase mRNAs in the rat midbrain: anatomical evidence and daily profiles
Malek, Z. S., Dardente, H., Pévet, P., & Raison, S. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04264.x · Cited by 125 · see citing works
Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders
Yu, Y. W. ‐., Tsai, S., Liou, Y., Hong, C., & Chen, T. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.12.004 · Cited by 124 · see citing works

Flagged first, then by citations

Sorted by citations

Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169 · see citing works
Time for united action on depression: a Lancet–World Psychiatric Association Commission
Herrman, H., Patel, V., Kieling, C., Berk, M., Buchweitz, C., Cuijpers, P., Furukawa, T. A., Kessler, R. C., Kohrt, B. A., Maj, M., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02141-3 · Cited by 1,104 · see citing works
Complexities ofCYP2D6gene analysis and interpretation
Gaedigk, A. (2013) · International Review of Psychiatry · doi:10.3109/09540261.2013.825581 · Cited by 224 · see citing works
Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial
AB-GEN Collaborative Group, Pérez, V., Salavert, A., Espadaler, J., Tuson, M., Sáiz-Ruiz, J., Sáez-Navarro, C., Bobes, J., Baca‐García, E., Vieta, E., et al. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1412-1 · Cited by 202 · see citing works
Pharmacogenetic Tests and Depressive Symptom Remission: A Meta-Analysis of Randomized Controlled Trials
Bousman, C., Arandjelovic, K., Mancuso, S. G., Eyre, H. A., & Dunlop, B. W. (2018) · Pharmacogenomics · doi:10.2217/pgs-2018-0142 · Cited by 204 · see citing works
Depressive disorders: treatment failures and poor prognosis over the last 50 years
Blackburn, T. P. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.472 · Cited by 136 · see citing works
Mechanisms of antidepressant resistance
El-Hage, W., Leman, S., Camus, V., & Belzung, C. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00146 · Cited by 111 · see citing works
Genetic variants in major depressive disorder: From pathophysiology to therapy
Gonda, X., Petschner, P., Eszlári, N., Baksa, D., Édes, A. E., Antal, P., Juhász, G., & Bagdy, G. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.09.002 · Cited by 88 · see citing works
Fast quantification of ten psychotropic drugs and metabolites in human plasma by ultra-high performance liquid chromatography tandem mass spectrometry for therapeutic drug monitoring
Ansermot, N., Brawand-Amey, M., Kottelat, A., & Eap, C. B. (2013) · Journal of Chromatography A · doi:10.1016/j.chroma.2012.12.071 · Cited by 87 · see citing works
Antidepressant prescribing in the precision medicine era: a prescriber’s primer on pharmacogenetic tools
Bousman, C., Forbes, M., Jayaram, M., Eyre, H. A., Reynolds, C. F., Berk, M., Hopwood, M., & Ng, C. H. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1230-5 · Cited by 72 · see citing works
DNA Methylation as a Biomarker of Treatment Response Variability in Serious Mental Illnesses: A Systematic Review Focused on Bipolar Disorder, Schizophrenia, and Major Depressive Disorder
Goud, A. C., Étain, B., Bellivier, F., & Cynthia Marie-claire, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103026 · Cited by 68 · see citing works
The role of glutamatergic, GABA-ergic, and cholinergic receptors in depression and antidepressant-like effect
Pytka, K., Dziubina, A., Młyniec, K., Dziedziczak, A., Żmudzka, E., Furgała, A., Olczyk, A., Sapa, J., & Filipek, B. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2015.10.006 · Cited by 63 · see citing works
Interplay between the key proteins of serotonin system in SSRI antidepressants efficacy
Kulikov, A. V., Gainetdinov, R. R., Ponimaskin, E. G., Kalueff, A. V., Naumenko, V. S., & Popova, N. K. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1452912 · Cited by 61 · see citing works
The Role of Pharmacogenetics in Personalizing the Antidepressant and Anxiolytic Therapy
Radosavljević, M., Štrac, D. Š., Jančić, J., & Samardžić, J. (2023) · Genes · doi:10.3390/genes14051095 · Cited by 62 · see citing works
The Escitalopram versus Electric Current Therapy for Treating Depression Clinical Study (ELECT-TDCS): rationale and study design of a non-inferiority, triple-arm, placebo-controlled clinical trial
Brunoni, A. R., Sampaio-Júnior, B., Moffa, A. H., Borrione, L., Nogueira, B. S., Aparicio, L. V. M., Veronezi, B. P., Moreno, M., Fernandes, R. A., Tavares, D. F., et al. (2015) · Sao Paulo Medical Journal · doi:10.1590/1516-3180.2014.00351712 · Cited by 56 · see citing works
Venlafaxine pharmacokinetics focused on drug metabolism and potential biomarkers
Magalhães, P. J., Alves, G., LLerena, A., & Falcão, A. C. (2014) · Drug metabolism and drug interactions · doi:10.1515/dmdi-2013-0053 · Cited by 57 · see citing works
Involvement of PI3K/Akt/GSK-3β signaling pathway in the antidepressant-like and neuroprotective effects of Morus nigra and its major phenolic, syringic acid
Dalmagro, A. P., Camargo, A., Rodrigues, A. L. S., & Zeni, A. L. B. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.108843 · Cited by 54 · see citing works
Contribution of brain dopamine, serotonin and opioid receptors in the mechanisms of neuroimmunomodulation: Evidence from pharmacological analysis
Idova, G. V., Лазаревна, А. Е., & Чейдо, М. А. (2012) · International Immunopharmacology · doi:10.1016/j.intimp.2012.02.010 · Cited by 49 · see citing works
Simultaneous quantification of selective serotonin reuptake inhibitors and metabolites in human plasma by liquid chromatography–electrospray mass spectrometry for therapeutic drug monitoring
Ansermot, N., Brawand-Amey, M., & Eap, C. B. (2012) · Journal of Chromatography B · doi:10.1016/j.jchromb.2011.12.028 · Cited by 45 · see citing works
Augmentation effect of ketamine by guanosine in the novelty-suppressed feeding test is dependent on mTOR signaling pathway
Camargo, A., Pazini, F. L., Rosa, J. M., Wolin, I. A. V., Moretti, M., da Rosa, P. B., Neis, V. B., & Rodrigues, A. L. S. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.05.017 · Cited by 44 · see citing works
A Review of Antidepressant Therapy in Primary Care
Kennedy, S. H. (2013) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.12r01420 · Cited by 40 · see citing works
Epigenetics of Depression
Lolak, S., Suwannarat, P., & Lipsky, R. H. (2014) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-800977-2.00005-x · Cited by 40 · see citing works
Comorbid Conditions in Chronic Obstructive Pulmonary Disease: Potential Therapeutic Targets for Unmet Needs
Matsunaga, K., Harada, M., Suizu, J., Oishi, K., Asami‐Noyama, M., & Hirano, T. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103078 · Cited by 40 · see citing works
Association of BDNF, HTR2A, TPH1, SLC6A4, and COMT polymorphisms with tDCS and escitalopram efficacy: ancillary analysis of a double-blind, placebo-controlled trial
Brunoni, A. R., Carracedo, Á., Maroñas, O., Latorre-Pellicer, A., Talib, L. L., Carvalho, A. F., Lotufo, P. A., Benseñor, I. M., Gattaz, W. F., & Cappi, C. (2019) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2019-0620 · Cited by 37 · see citing works
Does G2677T Polymorphism of the MDR1 Gene Make a Difference in the Therapeutic Response to Paroxetine in Depressed Patients in a Slovakian Population?
Vančová, Z., Čižmáriková, M., Dragašek, J., Zofcakova, S., Kolarčík, P., & Mojžíš, J. (2018) · Medical Science Monitor · doi:10.12659/msm.907434 · Cited by 35 · see citing works
Psychiatric Disorders - Trends and Developments
Uehara, T. (2011) · InTech eBooks · doi:10.5772/2330 · Cited by 35 · see citing works
Pharmacogenomic scores in psychiatry: systematic review of current evidence
Sharew, N. T., Clark, S. R., Schubert, K. O., & Amare, A. T. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02998-6 · Cited by 33 · see citing works
Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions
Launiainen, T., Rasanen, I., Vuori, E., & Ojanperä, I. A. (2010) · International Journal of Legal Medicine · doi:10.1007/s00414-010-0461-5 · Cited by 29 · see citing works
Novel Targets for Fast Antidepressant Responses: Possible Role of Endogenous Neuromodulators
Camargo, A., & Rodrigues, A. L. S. (2019) · Chronic Stress · doi:10.1177/2470547019858083 · Cited by 28 · see citing works
Therapeutic Drug Monitoring of Fluoxetine, Norfluoxetine and Paroxetine: A New Tool Based on Microextraction by Packed Sorbent Coupled to Liquid Chromatography
Magalhães, P., Alves, G., LLerena, A., & Falcão, A. C. (2017) · Journal of Analytical Toxicology · doi:10.1093/jat/bkx043 · Cited by 27 · see citing works
Vesicular signalling and immune modulation as hedonic fingerprints: proteomic profiling in the chronic mild stress depression model
Bisgaard, C. F., Bak, S. Y., Christensen, T. T., Jensen, O. N., Enghild, J. J., & Wiborg, O. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112460110 · Cited by 27 · see citing works
Influence of 5-HT1A and 5-HTTLPR genetic variants on the schizophrenia symptoms and occurrence of treatment-resistant schizophrenia
Plesničar, B. K., Terzić, T., Kastelic, M., & Dolžan, V. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s76494 · Cited by 27 · see citing works
Tryptophan Hydroxylase 2 Deficiency Modifies the Effects of Fluoxetine and Pargyline on the Behavior, 5-HT- and BDNF-Systems in the Brain of Zebrafish (Danio rerio)
Evsiukova, V. S., Базовкина, Д. В., Bazhenova, E., Kulikova, E. A., & Kulikov, A. V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312851 · Cited by 26 · see citing works
Additive Effects of 5-HTTLPR (Serotonin Transporter) and Tryptophan Hydroxylase 2 G-703T Gene Polymorphisms on the Clinical Response to Citalopram among Children and Adolescents with Depression and Anxiety Disorders
Rotberg, B., Kronenberg, S., Carmel, M., Frisch, A., Brent, D. A., Zalsman, G., Apter, A., & Weizman, A. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0020 · Cited by 25 · see citing works
Ursolic acid abrogates depressive-like behavior and hippocampal pro-apoptotic imbalance induced by chronic unpredictable stress
Colla, A. R. D. S., Pazini, F. L., Lieberknecht, V., Camargo, A., & Rodrigues, A. L. S. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-020-00658-4 · Cited by 25 · see citing works
Pathophysiology of Depression: Stingless Bee Honey Promising as an Antidepressant
Zakaria, F. H., Ismail, S., Mustafa, M. Z., & Shafin, N. (2022) · Molecules · doi:10.3390/molecules27165091 · Cited by 28 · see citing works
Role of Pharmacogenetics in Improving the Safety of Psychiatric Care by Predicting the Potential Risks of Mania in CYP2D6 Poor Metabolizers Diagnosed With Bipolar Disorder
Sánchez-Iglesias, S., García-Solaesa, V., Berrocal, B. G., Sánchez-Martín, A., Lorenzo-Romo, C., Martín-Pinto, T., Gaedigk, A., González‐Buitrago, J. M., & Isidoro‐García, M. (2016) · Medicine · doi:10.1097/md.0000000000002473 · Cited by 24 · see citing works
Therapygenetics: 5-HTTLPR genotype predicts the response to exposure therapy for agoraphobia
Knuts, I., Esquivel, G., Kenis, G., Overbeek, T., Leibold, N. K., Goossens, L., & Schruers, K. R. J. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.05.007 · Cited by 23 · see citing works
Serotonin Transporter Gene: A New Polymorphism May Affect Response to Antidepressant Treatments in Major Depressive Disorder
Matsumoto, Y., Fabbri, C., Pellegrini, S., Porcelli, S., Politi, P., Bellino, S., Iofrida, C., Mariotti, V., Melissari, E., Menchetti, M., et al. (2014) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-014-0110-7 · Cited by 23 · see citing works
Self-citation
Antidepressant‐Like Effect of Lipid Extract of Channa striatus in Chronic Unpredictable Mild Stress Model of Depression in Rats
Shukkoor, M. S. A., Baharuldin, M. T. H., Jais, A. M. M., Moklas, M. A. M., & Fakurazi, S. (2016) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2016/2986090 · Cited by 23 · see citing works
Facile design of lidocaine-loaded polymeric hydrogel to persuade effects of local anesthesia drug delivery system: complete in vitro and in vivo toxicity analyses
Li, Y., Zhao, E., Li, L., Bai, L., & Zhang, W. (2021) · Drug Delivery · doi:10.1080/10717544.2021.1931558 · Cited by 22 · see citing works
Utility of pharmacogenetic testing to optimise antidepressant pharmacotherapy in youth: a narrative literature review
Roberts, B., Cooper, Z., Lu, S., Stanley, S., Majda, B. T., Collins, K. R., Gilkes, L., Rodger, J., Akkari, P., & Hood, S. D. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1267294 · Cited by 19 · see citing works
Preclinical models of treatment-resistant depression: challenges and perspectives
Kolasa, M., & Faron‐Górecka, A. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00542-9 · Cited by 22 · see citing works
Detection and Characterization of the CYP2D6*9x2 Gene Duplication in two Spanish Populations: Resolution of AmpliChip CYP450 test No-Calls
Gaedigk, A., Hernandez-Sanchez, J., García-Solaesa, V., Sánchez, S., & Isidoro‐García, M. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.107 · Cited by 19 · see citing works
A Case Study of the Utility of the HapMap Database for Pharmacogenomic Haplotype Analysis in the Taiwanese Population
Lin, E., Hwang, Y., & Tzeng, C. (2006) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256213 · Cited by 19 · see citing works
Genetic Markers for Later Remission in Response to Early Improvement of Antidepressants
Kang, H., Kim, K., Yoo, K.-H., Park, Y., Kim, J., Kim, J., Shin, I.-S., Kim, J. H., & Kim, J. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144884 · Cited by 17 · see citing works
Guanosine potentiates the antidepressant-like effect of subthreshold doses of ketamine: Possible role of pro-synaptogenic signaling pathway
Camargo, A., Dalmagro, A. P., Zeni, A. L. B., & Rodrigues, A. L. S. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.186 · Cited by 16 · see citing works
Concurrent determination of olanzapine, risperidone and 9‐hydroxyrisperidone in human plasma by ultra performance liquid chromatography with diode array detection method: application to pharmacokinetic study
Kumar, M. S. S., & Ramanathan, M. (2015) · Biomedical Chromatography · doi:10.1002/bmc.3545 · Cited by 15 · see citing works
Pharmacogenetics: a reality or misplaced optimism?
Mutsatsa, S., & Currid, T. (2012) · Journal of Psychiatric and Mental Health Nursing · doi:10.1111/j.1365-2850.2012.01910.x · Cited by 15 · see citing works
The development and validation of a turbulent flow-liquid chromatography–tandem mass spectrometric method for the simultaneous quantification of citalopram, sertraline, bupropion and hydroxybupropion in serum
Petrides, A. K., Moskowitz, J., Johnson‐Davis, K. L., Jannetto, P. J., Langman, L. J., Clarke, W. A., & Marzinke, M. A. (2014) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2014.07.018 · Cited by 15 · see citing works
Clinical, Research and Treatment Approaches to Affective Disorders
Juruena, M. F. (2012) · InTech eBooks · doi:10.5772/1482 · Cited by 7 · see citing works
Harnessing Pharmacogenomics in Clinical Research on Psychedelic‐Assisted Therapy
Halman, A., Conyers, R. K., Moore, C., Khatri, D., Sarris, J. J., & Perkins, D. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3459 · Cited by 13 · see citing works
First MEPS/HPLC Assay for The Simultaneous Determination of Venlafaxine and O -Desmethylvenlafaxine in Human Plasma
Magalhães, P. J., Alves, G., Rodrigues, M., LLerena, A., & Falcão, A. C. (2014) · Bioanalysis · doi:10.4155/bio.14.222 · Cited by 13 · see citing works
Endocannabinoid Regulation of Monoamines in Psychiatric and Neurological Disorders
Bockstaele, E. J. V. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7940-6 · Cited by 13 · see citing works
Genetic influences on antidepressant side effects: a CYP2C19 gene variation and polygenic risk study in the Estonian Biobank
Kariis, H. M., Särg, D., Krebs, K., Lepamets, M., Kõiv, K., Sirts, K., Hudjashov, G., Särg, D., Alver, M., Lehto, K., et al. (2025) · European Journal of Human Genetics · doi:10.1038/s41431-025-01894-x · Cited by 12 · see citing works
Pharmacogenetic studies: a tool to improve antidepressant therapy
Ramos, M., Berrogain, C., Concha, J., Lomba, L., García, C. B., & Ribate, M. P. (2016) · Drug Metabolism and Personalized Therapy · doi:10.1515/dmpt-2016-0019 · Cited by 12 · see citing works
Role of serotonin transporter and receptor gene polymorphisms in treatment response to selective serotonin reuptake inhibitors in major depressive disorder
Ramesh, V., Venkatesan, V., & Ramasamy, B. (2022) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2830 · Cited by 12 · see citing works
Pharmacokinetics and Safety of Vortioxetine in the Chinese Population
Miao, J., Wang, G., Hou, J., Areberg, J., Zhao, Y., Højer, A., & Ettrup, A. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01092-4 · Cited by 10 · see citing works
Role of Pharmacokinetics and Pharmacogenetics of Antidepressant-Induced Prolongation of the QT Interval and Torsade de Pointes in Patients with Mental Disorders
Shnayder, N. A., Kidyaeva, A. V., Vaiman, E. E., Asadullin, A. R., Петрова, М. М., Kaskaeva, D. S., Matyushin, G. V., Evsyukov, A. A., Galko, E. V., Garganeeva, N. P., et al. (2023) · Personalized Psychiatry and Neurology · doi:10.52667/2712-9179-2023-3-2-72-119 · Cited by 10 · see citing works
Prescription Pattern of Antidepressants and the Potential for Personalized Medicine in the Qatari Population
Bastaki, K., Anbari, M. E., Ghuloum, S., & Jithesh, P. V. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11050406 · Cited by 9 · see citing works
L. Cucurbita pepo Alleviates Chronic Unpredictable Mild Stress via Modulation of Apoptosis, Neurogenesis, and Gliosis in Rat Hippocampus
Ayuob, N. N., Ali, S. S., Hawuit, E., Al-Abbas, N. S., Shaer, N. A., Jaouni, S. K. A., & Mahdi, M. R. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6662649 · Cited by 9 · see citing works
Pharmacogenetic considerations for late life depression therapy
Pitychoutis, P. M., Kokras, N., Sanoudou, D., Dalla, C., & Papadopoulou‐Daifoti, Z. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.794786 · Cited by 9 · see citing works
Female Sexual Dysfunction in Patients with Major Depressive Disorder (MDD) Treated with Selective Serotonin Reuptake Inhibitor (SSRI) and Its Association with S erotonin 2A—1438 G/A Single Nucleotide Polymorphisms
Masiran, R., Sidi, H., Mohamed, Z., Nazree, N. E., Jaafar, N. R. N., Midin, M., Das, S., & Saini, S. M. (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12452 · Cited by 9 · see citing works
Centrally Administered Cortistation-14 Induces Antidepressant-Like Effects in Mice via Mediating Ghrelin and GABAA Receptor Signaling Pathway
Jiang, J., Peng, Y., Liang, X., Li, S., Chang, X., Li, L., & Chang, M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00767 · Cited by 9 · see citing works
Association of Periodic Limb Movements With Medication Classes
Hoxha, O., Jairam, T., Kendzerska, T., Rajendram, P., Zhou, R., Ravindran, P., Osman, S., Banayoty, M., Qian, Y., Murray, B. J., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000200012 · Cited by 8 · see citing works
Clinical implications of pharmacogenetic and microarray testing for advanced practice nurses
Brennan, K. S. (2015) · Journal of the American Association of Nurse Practitioners · doi:10.1002/2327-6924.12237 · Cited by 8 · see citing works
Do we need new therapeutic strategies for depression?
Mihaljević-Peleš, A., Šagud, M., Janović, M. B., Mikulić, S. K., & Jevtović, S. (2011) · PubMed · Cited by 8 · see citing works
Do we need pharmacogenetics to personalize antidepressant therapy?
Lanni, C., Racchi, M., & Govoni, S. M. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1237-5 · Cited by 7 · see citing works
Interactive effects of citalopram and serotonin transporter genotype on neural correlates of response inhibition and attentional orienting
Fischer, A. G., Endraß, T., Goebel, I., Reuter, M., Montag, C., Kubisch, C., & Ullsperger, M. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2015.04.064 · Cited by 8 · see citing works
Can the CEIBA Cocktail Designed for Human Cytochrome P450 Enzymes be Used in the Rat for Drug Interaction Studies?
Magalhães, P. J., de Andrés, F., Falcão, A. C., LLerena, A., & Alves, G. (2016) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3d313 · Cited by 7 · see citing works
Spectroscopic methods to analyze drug metabolites
Yi, J.-J., Park, K., Kim, W.-J., Rhee, J., & Son, W. S. (2018) · Archives of Pharmacal Research · doi:10.1007/s12272-018-1010-x · Cited by 7 · see citing works
Pharmacogenetic/Pharmacogenomic Tests for Treatment Prediction in Depression
Islam, F., Gorbovskaya, I., & Müller, D. J. (2021) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-33-6044-0_13 · Cited by 6 · see citing works
Pathophysiology of Mood Disorders and Mechanisms of Action of Antidepressants and Mood Stabilizers
Fišar, Z. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7940-6_6 · Cited by 7 · see citing works
ROLE OF ENZYMES IN THE PATHOGENESIS OF DEPRESSION
Walia, V. (2016) · Journal of Critical Reviews · Cited by 5 · see citing works
Antidepressant Prescribing in the Precision Medicine Era: a Prescriber's Primer on Pharmacogenetic Tools
Bousman, C., Forbes, M., Jayaram, M., Eyre, H. A., Reynolds, C. F., Berk, M., Hopwood, M., & Ng, C. H. (2018) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.16204 · Cited by 5 · see citing works
Precision Psychiatry: Personalized Clinical Approach to Depression
Perna, G., Balletta, R., & Nemeroff, C. B. (2017) · Springer eBooks · doi:10.1007/978-981-10-6580-4_21 · Cited by 5 · see citing works
Pharmacogenetics and Analgesic Effects of Antidepressants in Chronic Pain Management
Rodieux, F., Piguet, V., Berney, P., Desmeules, J. A., & Besson, M. J. (2015) · Personalized Medicine · doi:10.2217/pme.14.61 · Cited by 5 · see citing works
Cytotoxic Effect of Escitalopram/Etoposide Combination on Etoposide-Resistant Lung Cancer
Gül, S. Ö., Şimşek, B., Yıldız, F., & Aydemir, E. A. (2025) · Pharmaceuticals · doi:10.3390/ph18040531 · Cited by 4 · see citing works
Neurotransmission in Mood Disorders
Fiar, Z., Hroudov, J., & Raboch, J. (2012) · InTech eBooks · doi:10.5772/31831 · Cited by 4 · see citing works
Pharmacogenomic Testing for Postoperative Pain Optimization Before Total Joint Arthroplasty
Awad, M. E., Padela, M. T., Sayeed, Z., El‐Othmani, M. M., Zekaj, M., Darwiche, H. F., & Saleh, K. J. (2019) · JBJS Reviews · doi:10.2106/jbjs.rvw.18.00058 · Cited by 3 · see citing works
Pharmacogenetics of Antidepressants: from Genetic Findings to Predictive Strategies
Khokhlov, L. K., & Lukyanov, N. E. (2019) · Бюллетень Восточно-Сибирского научного центра Сибирского отделения Российской академии медицинских наук · doi:10.29413/abs.2019-4.2.5 · Cited by 3 · see citing works
Biological Alterations in Depression
Benton, C. S., & Wiltshire, T. (2011) · InTech eBooks · doi:10.5772/27658 · Cited by 3 · see citing works
Toxicokinetics and Toxicogenetics
Meyer, M. R., & Maurer, H. H. (2014) · doi:10.1002/9781118570654.ch50 · Cited by 3 · see citing works
Pharmacogenetic Testing to Optimise Antidepressant Treatment in Children and Adolescents: A Narrative Review
Perez, J., Gonzalez, M., & Ramirez, S. (2024) · Specialty Journal of Pharmacognosy, Phytochemistry, and Biotechnology · doi:10.51847/rmgserramc
Experimental and pharmacoinformatic approaches unveil the neuropharmacological and analgesic potential of chloroform fraction of Roktoshirinchi (Achyranthes ferruginea Roxb.)
Reza, A. S. M. A., Raihan, R., Azam, S., Shahanewz, M., Nasrin, M. S., Siddique, M. A. B., Uddin, M. N., Dey, A. K., Sadik, G., & Alam, A. K. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.117769 · Cited by 2 · see citing works
Current state and potential of pharmacogenetic studies in the treatment of depression
Ivanets, N. N., Tikhonova, Y. G., Kinkulkina, M. A., & Avdeeva, T. I. (2015) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro201511531113-121 · Cited by 2 · see citing works
Drug-metabolizing enzymes and fate of prodrugs: From function to regulation
Mallhi, T. H., Butt, M. H., Ahmad, A., Misbah, S., Salman, M., Khan, A., Raja, A. A., & Khan, Y. H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-95120-3.00005-1 · Cited by 2 · see citing works
Cognitive-reminiscence therapy for the treatment of depression in young adults
Hallford, D. J. (2013) · Cited by 3 · see citing works
Importance of Pharmacogenomics
Zanger, U. M., Klein, K., & Rieger, J. K. (2012) · doi:10.1002/9783527630905.ch9 · Cited by 2 · see citing works
Genetic variability ofCYP2D6:basic and clinical aspects
Zanger, U. M. (2014) · doi:10.2217/fmeb2013.13.130 · Cited by 2 · see citing works
Pharmacogenomic scores in psychiatry: Systematic review of existing evidencePreprint
Sharew, N. T., Clark, S. R., Schubert, K. O., & Amare, A. T. (2024) · medRxiv · doi:10.1101/2024.04.05.24305376 · Cited by 2 · see citing works
An observational feasibility study on the impact of green exposure on major depressive episode symptomatology and inflammatory biomarkers
Pavarino, G., Brasso, C., Boido, M., Carluccio, A., Cirulli, F., Mengozzi, G., Schellino, R., Vercelli, A., & Rocca, P. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1631393 · Cited by 1 · see citing works
Pharmacogenetics of antidepressant drugs: An update
Crisafulli, C., Drago, A., Calabrò, M., Sidoti, A., Serretti, A., & Spina, E. (2014) · Hospital Pharmacology - International Multidisciplinary Journal · doi:10.5937/hpimj1401033c · Cited by 1 · see citing works
Self-citation
Association between ABC family polymorphisms and antidepressant response in Chinese Han population with major depressive disorder
Ma, G., Huang, X., Xu, F., Ren, D., Bi, Y., Guo, Z., Yuan, F., Sun, Q., Zhang, N., An, L., et al. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.112615 · Cited by 1 · see citing works
Impaired mitochondrial bioenergetics in psychiatric disorders
Petschner, P., Gál, Z., & Gonda, X. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819621-2.00008-5 · Cited by 1 · see citing works
Pharmacogenetics of antidepressants: A step to individualized therapy
Samardžić, J. (2020) · Srpski medicinski casopis Lekarske komore · doi:10.5937/smclk2001013s · Cited by 1 · see citing works
Precision Medicine in Psychotherapy: The Past, Present and Future
Sukumaran, B., Sharumathi, S. M., Xavier, R. M., Arun, K. P., & Deepalakshmi, M. (2024) · International Journal of Pharmaceutical Quality Assurance · doi:10.25258/ijpqa.15.1.75 · Cited by 1 · see citing works
Effects of Remission and Genetic Variation on Brain Structure in Treatment-Resistant Major Depressive Disorder: A Prospective, Longitudinal Imaging Study
Phillips, J. L. (2015) · uO Research (University of Ottawa) · doi:10.20381/ruor-2800
Substratos neurais envolvidos com o desenvolvimento do comportamento de desamparo em ratos: possível envolvimento do NO
Sato, V. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2017.tde-20072016-091556
CYP2D6: clinical implications in neuropsychiatry
Baumann, P. (2014) · doi:10.2217/fmeb2013.14.10

Genetics of treatment response in depression
Drago, A. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.07.357
Self-citation
Reviewed by:
Crisafulli, C., Fabbri, C., Porcelli, S., Drago, A., Spina, E., Ronchi, D. D., Serretti, R., Margarete, K. K. D., & Eap, C. (2011)
Self-citation
Insights from pharmacogenetic studies of antidepressants
Mandelli, L. (2010) · Annals of General Psychiatry · doi:10.1186/1744-859x-9-s1-s8
Genetics and Personalized Medicine in Antidepressant Treatment
Gvozdic, K., Brandl, E. J., Taylor, D. L., & Müller, D. J. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212803523617 · Cited by 25 · see citing works
The pharmacogenetics of antidepressant treatments for depressive disorders
Lee, M.-S. (2005) · Drug Development Research · doi:10.1002/ddr.20020 · Cited by 5 · see citing works

Authors: Crisafulli, C., Fabbri, C., Porcelli, S., Drago, A., Spina, E., De Ronchi, D., & Serretti, A.
Affiliations: University of Messina (IT)
University of Bologna (IT)
Corresponding author: Spina, Edoardo
ORCID: Crisafulli, Concetta
Fabbri, Chiara
Porcelli, Stefano
Drago, Antonio
Spina, Edoardo
Serretti, Alessandro
Venue: Frontiers in Pharmacology
Publisher: Frontiers Media SA
Published: 2011
Volume: 2
Pages: 6-6
ISSN: 1663-9812 (ISSN-L)
DOI: 10.3389/fphar.2011.00006
PMC: PMC3108562
OpenAlex: W2142351553
Cited by: 113
References: 418
Citations by year: 2026: 5 · 2025: 5 · 2024: 6 · 2023: 4 · 2022: 6 · 2021: 6 · 2020: 5 · 2019: 12 · 2018: 9 · 2017: 6 · 2016: 5 · 2015: 9 · 2014: 11 · 2013: 10 · 2012: 8
FWCI: 4.37
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
Locations: Frontiers in Pharmacology (publishedVersion, cc-by)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords: pharmacogenetics, antidepressants, antidepressant response, depression, candidate genes, cytochrome P450, tryptophan hydroxylase, catechol-O-methyltransferase, monoamine oxidase A, norepinephrine transporter, dopamine transporter, serotonin receptors, adrenergic receptors, dopamine receptors, corticotropin-releasing factor receptor, glucocorticoid receptor, CREB, brain-derived neurotrophic factor, gene-environment interaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pharmacogenetics of antidepressants

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks